Want to see PRPO full AI Analyst Report?
PRPO Stock Chart & Stats
$30.40
$0.07(0.31%)
At close: 4:00 PM EDT
$30.40
$0.07(0.31%)
Day’s Range― - ―
52-Week Range$18.50 - $33.63
Previous CloseN/A
Volume67.76K
Average Volume (3M)73.58K
Market Cap
$35.82M
Enterprise Value$44.77M
Total Cash (Recent Filing)$3.08M
Total Debt (Recent Filing)$3.34M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding1,790,188
10 Day Avg. Volume44,525
30 Day Avg. Volume73,584
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)2.53
Price to Sales (P/S)1.53
P/FCF Ratio102.74
Enterprise Value/Market Cap1.25
Enterprise Value/Revenue1.63
Enterprise Value/Gross Profit3.73
Enterprise Value/Ebitda74.61
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27.4
Revenue Forecast (FY)$80.26M
Bulls Say, Bears Say
Bulls Say
Revenue And Product GrowthStrong top-line growth and accelerating product sales indicate improving demand across Precipio’s diagnostics platform. If sustained, the expanding revenue base can support operating leverage, broaden customer adoption, and strengthen the company’s competitive position in oncology testing.
Improved Cash GenerationThe shift to positive operating and free cash flow materially improves financial resilience after several years of weak cash generation. Internally funded operations reduce reliance on external capital and give management greater flexibility to support commercialization and product development.
Conservative Balance SheetManageable leverage and substantial equity provide a relatively stable financial foundation for a small diagnostics company. This capitalization reduces balance-sheet pressure, improves the ability to absorb operating volatility, and leaves more flexibility for continued investment in growth initiatives.
Bears Say
Persistent GAAP LossesDespite better revenue and cash-flow trends, Precipio has not yet established consistent GAAP profitability. Continued losses can constrain reinvestment, weaken returns on equity, and make future performance dependent on sustaining growth and converting operational improvements into durable earnings.
Commercial Execution RiskThe growth opportunity depends on turning new distributor representatives, qualified customers, and meetings into recurring commercial accounts. Failure to convert this pipeline could leave recent sales momentum below expectations and delay the operating leverage needed to reach durable profitability.
Slow Core Pathology GrowthThe limited sequential growth in the core pathology business suggests that the established services base is not currently expanding rapidly. Greater reliance on newer product commercialization raises execution demands and could make consolidated growth less balanced if product adoption takes longer.
Precipio News
PRPO FAQ
What was Precipio Inc’s price range in the past 12 months?
Precipio Inc lowest stock price was $18.50 and its highest was $33.63 in the past 12 months.
What is Precipio Inc’s market cap?
Precipio Inc’s market cap is $35.82M.
When is Precipio Inc’s upcoming earnings report date?
Precipio Inc’s upcoming earnings report date is Nov 16, 2026 which is in 22 days.
How were Precipio Inc’s earnings last quarter?
Precipio Inc released its earnings results on Aug 14, 2026. The company reported -$0.122 earnings per share for the quarter.
Is Precipio Inc overvalued?
According to Wall Street analysts Precipio Inc’s price is currently Overvalued.
Does Precipio Inc pay dividends?
Precipio Inc does not currently pay dividends.
What is Precipio Inc’s EPS estimate?
Precipio Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Precipio Inc have?
Precipio Inc has 1,790,188 shares outstanding.
What happened to Precipio Inc’s price movement after its last earnings report?
Precipio Inc reported an EPS of -$0.122 in its last earnings report. Following the earnings report the stock price went up 1.702%.
Which hedge fund is a major shareholder of Precipio Inc?
Currently, no hedge funds are holding shares in PRPO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Precipio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
PRPO Sentiment 75%
Sector Average 66%
Sector Average 66%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.71%
12-Months-Change
Fundamentals
Return on Equity
-8.49%
Trailing 12-Months
Asset Growth
13.31%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Precipio Inc
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
PRPO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple meaningful operational and financial improvements: record quarterly revenue (> $7M), strong product revenue acceleration (+35% sequential, +21% vs prior record), positive adjusted EBITDA (~$400K) and $700K operating cash generation leading to a >$3M cash balance. These positives are tempered by modest pathology sequential growth, prior distributor complexity that slowed past ramping, quarter-to-quarter timing/seasonality effects, noted execution risk to convert the expanded pipeline, and an unexplained spike in share trading. On balance, the company emphasized organic improvement and execution plans to sustain growth.View all PRPO earnings summariesTechnical Analysis
Ownership Overview
10.91% Insiders
2.27% Mutual Funds
1.91% Other Institutional Investors
81.08% Public Companies and
Individual Investors